Opus Point Partners Management’s Kyntra Bio KYNB Stock Holding History

Opus Point Partners Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$212K	Buy	230 +35	+18%	+$38.4K	0.38%	54
2019 Q2	$221K	Buy	195 +2	+1%	+$2.19K	0.33%	62
2019 Q1	$262K	Sell	193 -75	-28%	-$102K	0.36%	66
2018 Q4	$310K	Sell	268 -418	-61%	-$470K	0.68%	25
2018 Q3	$1.04M	Sell	686 -51	-7%	-$78.5K	2.49%	17
2018 Q2	$1.15M	Buy	737 +6	+0.8%	+$7.82K	2.5%	14
2018 Q1	$845K	Buy	731 +554	+313%	+$730K	1.66%	22
2017 Q4	$210K	Buy	+177	New	+$222K	0.18%	59

Other funds holding KYNB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Opus Point Partners Management's KYNB Position: Q3 2019 in Review

Opus Point Partners Management increased its Kyntra Bio (KYNB) stake by 18% in Q3 2019, buying an estimated $38.4K and bringing the position to 230 shares worth $212K. The position accounts for 0.38% of the portfolio, ranked #54.

Opus Point Partners Management first reported a position in KYNB in Q4 2017 and has held it in 8 quarters since. The position peaked at $1.15M in Q2 2018. 210 funds tracked by Wall St. Rank hold KYNB as of Q3 2019.

Opus Point Partners Management held 230 shares of Kyntra Bio worth $212K as of Q3 2019.
Opus Point Partners Management bought 35 Kyntra Bio shares in Q3 2019, an estimated $38.4K.
Kyntra Bio made up 0.38% of Opus Point Partners Management's portfolio in Q3 2019, its #54 holding.
Opus Point Partners Management first reported a position in Kyntra Bio in Q4 2017 and has held it in 8 quarters since.
Opus Point Partners Management's Kyntra Bio position peaked at $1.15M in Q2 2018.
210 funds tracked by Wall St. Rank held Kyntra Bio as of Q3 2019.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.